INTERVENTION 1:	Intervention	0
Metformin + Lifestyle Intervention	Intervention	1
metformin	CHEBI:6801	0-9
Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time	Intervention	2
metformin	CHEBI:6801	0-9
week	UO:0000034	11-15
week	UO:0000034	41-45
week	UO:0000034	75-79
time	PATO:0000165	36-40
time	PATO:0000165	70-74
time	PATO:0000165	122-126
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.	Intervention	3
weight loss	HP:0001824	106-117
INTERVENTION 2:	Intervention	4
Placebo + Lifestyle Intervention	Intervention	5
Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time	Intervention	6
week	UO:0000034	9-13
week	UO:0000034	39-43
week	UO:0000034	73-77
time	PATO:0000165	34-38
time	PATO:0000165	68-72
time	PATO:0000165	120-124
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.	Intervention	7
weight loss	HP:0001824	106-117
Inclusion Criteria:	Eligibility	0
BMI at least 25.0 kg/m2	Eligibility	1
Diagnosed with Stage I, II, or III breast cancer within past 5 years	Eligibility	2
breast cancer	DOID:1612	35-48
Treatment with total mastectomy or breast-sparing surgical removal of cancer with clear macroscopic margins, and axillary dissection, followed by adjuvant breast radiation	Eligibility	3
cancer	DOID:162	70-76
adjuvant	CHEBI:60809	146-154
breast	UBERON:0000310	35-41
breast	UBERON:0000310	155-161
Not scheduled for or currently undergoing chemotherapy	Eligibility	4
Accessible geographically and by telephone	Eligibility	5
Able to communicate dietary and physical activity data via telephone	Eligibility	6
If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on treatment for 6-month study period	Eligibility	7
tamoxifen	CHEBI:41774	19-28
Post-menopausal at diagnosis	Eligibility	8
Exclusion Criteria:	Eligibility	9
Preliminary bloodwork outside of specified ranges	Eligibility	10
Evidence of renal insufficiency, liver disease, or congestive heart failure	Eligibility	11
renal insufficiency	HP:0000083	12-31
liver disease	DOID:409	33-46
congestive heart failure	HP:0001635,DOID:6000	51-75
Currently taking corticosteroid pills or steroid hormone therapy (including vaginal estrogen creams)	Eligibility	12
corticosteroid	CHEBI:50858	17-31
steroid hormone	CHEBI:26764	41-56
estrogen	CHEBI:50114,BAO:0000760	84-92
Recent initiation (< 3 months ago) of thiazides or Î²-blockers	Eligibility	13
Taking insulin or other antidiabetic drug	Eligibility	14
insulin	CHEBI:145810	7-14
drug	CHEBI:23888	37-41
Other primary or recurrent invasive cancer in past 10 years	Eligibility	15
recurrent	HP:0031796	17-26
cancer	DOID:162	36-42
Unable to commit to study requirements	Eligibility	16
Outcome Measurement:	Results	0
Insulin	Results	1
insulin	CHEBI:145810	0-7
Insulin measured as percent change from baseline	Results	2
insulin	CHEBI:145810	0-7
percent change	BAO:0001252	20-34
Time frame: change from baseline to 6 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Metformin + Lifestyle Intervention	Results	5
metformin	CHEBI:6801	17-26
Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time	Results	6
metformin	CHEBI:6801	23-32
week	UO:0000034	34-38
week	UO:0000034	64-68
week	UO:0000034	98-102
time	PATO:0000165	59-63
time	PATO:0000165	93-97
time	PATO:0000165	145-149
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.	Results	7
weight loss	HP:0001824	106-117
Overall Number of Participants Analyzed: 83	Results	8
Least Squares Mean (95% Confidence Interval)	Results	9
mean	BAO:0002173	14-18
Unit of Measure: percent change from baseline  -21.8        (-29.7 to -13.0)	Results	10
percent change	BAO:0001252	17-31
Results 2:	Results	11
Arm/Group Title: Placebo + Lifestyle Intervention	Results	12
Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time	Results	13
week	UO:0000034	32-36
week	UO:0000034	62-66
week	UO:0000034	96-100
time	PATO:0000165	57-61
time	PATO:0000165	91-95
time	PATO:0000165	143-147
Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.	Results	14
weight loss	HP:0001824	106-117
Overall Number of Participants Analyzed: 83	Results	15
Least Squares Mean (95% Confidence Interval)	Results	16
mean	BAO:0002173	14-18
Unit of Measure: percent change from baseline  -17.7        (-25.9 to -8.6)	Results	17
percent change	BAO:0001252	17-31
Adverse Events 1:	Adverse Events	0
Total: 5/333 (1.50%)	Adverse Events	1
transient ischemic attack1/333 (0.30%)	Adverse Events	2
transient	HP:0025153	0-9
Injury due to fall1/333 (0.30%)	Adverse Events	3
Abdominal pain1/333 (0.30%)	Adverse Events	4
slurred speach1/333 (0.30%)	Adverse Events	5
Adverse Events 2:	Adverse Events	6
Total: 5/333 (1.50%)	Adverse Events	7
transient ischemic attack1/333 (0.30%)	Adverse Events	8
transient	HP:0025153	0-9
Injury due to fall1/333 (0.30%)	Adverse Events	9
Abdominal pain1/333 (0.30%)	Adverse Events	10
slurred speach1/333 (0.30%)	Adverse Events	11
